

What is claimed is

1. A package for storing medical devices in a solution comprising a molded base wherein the molded base comprises an additive, provided that
5 the medical device is not a contact lens consisting of acqualfilcon A coated with polyHema.
2. The package of claim 1 wherein the additive is selected from the group consisting of succinic acid, glycerol monostearate, PVP, and PVP/maleic
10 anhydride.
3. The package of claim 1 wherein the additive is glycerol monostearate.
4. The package of claim 3 wherein glycerol monostearate is present at a
15 concentration of greater than about 0.5 weight percent to about 5 weight percent.
5. The package of claim 3 wherein glycerol monostearate is present at a concentration of about 2 percent.
20
6. The package of claim 1 wherein the additive is PVP KD90.
7. The package of claim 6 wherein the PVP concentration is about 1% to about 5%.
25
8. The package of claim 6 wherein the PVP concentration is about 1.0%.
9. The package of claim 1 wherein the additive is PVP KD90/maleic anhydride.
30
10. The package of claim 9 wherein the PVP KD90/maleic anhydride concentration is about 1/1% to about 5/5%.

VTN 632 USNP

11. The package of claim 1 wherein the medical device is a contact lens which comprises balafilcon A, lotrafilcon A, galyfilcon, senofilcon, or lenses disclosed in U.S. Pat. App. No. 60/318,536, entitled Biomedical Devices Containing Internal wetting Agents," filed on September 10, 2001 and its non-provisional counterpart of the same title, filed on September 6, 2002.
12. The package of claim 11 wherein the contact lens comprises Simma 2 and mPDMS.
13. The package of claim 11 wherein the contact lens comprises Simma 2
14. The package of claim 1 wherein the molded base comprises polypropylene.
15. The package of claim 1 further comprising a cavity formed in said molded base wherein said cavity comprises an inner surface, wherein said inner surface has an average roughness of about 0.5 μm to about 20 μm .
16. The package of claim 15 wherein the inner surface has an average roughness of about 1.8 μm to about 4.5 μm .
17. The package of claim 15 wherein the inner surface has an average roughness of about 1.9 μm to about 2.1 μm
18. The package of claim 15 wherein the inner surface has an average roughness of about 0.5 μm to about 0.8 μm .
19. The package of claim 1 further comprising a cavity formed in said molded base wherein said cavity comprises an inner surface, wherein said inner surface has an average roughness of about 0.5 μm to about 20 μm and the additive is glycerol monostearate or PVP.

VTN 632 USNP

20. The package of claim 19 wherein the average roughness of the inner surface is about 0.5 μm to about 0.8 μm and the concentration of PVP is about 1%.
- 5 21. The package of claim 19 wherein the inner surface has an average roughness of about 1.9 μm to about 2.1 μm and the concentration of PVP is about 1%.
- 10 22. The package of claim 1 further comprising a cavity formed in said molded base wherein said cavity comprises an inner surface, wherein said inner surface has an average roughness of about 0.5 μm to about 20 μm and the additive is maleic anhydride or PVP/maleic anhydride.
- 15 23. The package of claim 22 wherein the average roughness of the inner surface is about 0.5 μm to about 0.8 μm and the concentration of PVP/maleic anhydride is about 1%.
- 20 24. The package of claim 22 wherein the inner surface has an average roughness of about 1.9 μm to about 2.1 μm and the concentration of PVP/maleic anhydride is about 1%.
- 25 25. The package of claim 22 wherein the average roughness of the inner surface is about 0.5 μm to about 0.8 μm and the concentration of maleic anhydride is about 1%.
26. The package of claim 22 wherein the inner surface has an average roughness of about 1.9 μm to about 2.1 μm and the concentration of maleic anhydride is about 1%.
- 30 27. A method of reducing the adherence of a medical device to its packaging, comprising storing said medical device in a solution in a package comprising a molded base wherein said molded base comprises an additive,

VTN 632 USNP

provided that the medical device is not a contact lens consisting of acqualfilcon A coated with polyHema.

28. The method of claim 27 wherein additive is selected from the group
5 consisting of succinic acid, glycerol monostearate, and PVP.
29. The method of claim 27 wherein the additive is glycerol monostearate.
30. The method of claim 27 wherein glycerol monostearate is present at a
10 concentration of greater than about 0.25 weight percent to about 5 weight percent.
31. The method of claim 27 wherein glycerol monostearate is present at a
concentration of about 2 percent.
15
32. The method of claim 27 wherein the additive is PVP KD90.
33. The method of claim 27 wherein the PVP is present at about 1% to
about 5%.
20
34. The method of claim 27 wherein the contact lens comprises balafilcon
A, lotrafilcon A, or lenses disclosed in U.S. Pat. App. No. 60/318,536, entitled
Biomedical Devices Containing Internal wetting Agents," filed on September
10, 2001 and its non-provisional counterpart of the same title, filed on
25 September 6, 2002.
35. The method of claim 27 wherein the contact lens comprises Simma 2
36. The method of claim 27 wherein the molded base comprises
30 polypropylene.

VTN 632 USNP

37. The method of claim 27 further comprising a cavity formed in said molded base wherein said cavity comprises an inner surface, wherein said inner surface has an average roughness of about 0.5 μm to about 20 μm and the additive is glycerol monostearate or PVP.

5

38. The method of claim 37 wherein the average roughness of the inner surface is about 0.5 μm to about 0.8 μm and the concentration of PVP is about 1%.

10 39. The method of claim 37 wherein the inner surface has an average roughness of about 1.9 μm to about 2.1 μm and the concentration of PVP is about 1%.

15 40. The method of claim 27 further comprising a cavity formed in said molded base wherein said cavity comprises an inner surface, wherein said inner surface has an average roughness of about 0.5 μm to about 20 μm and the additive is maleic anhydride or PVP/maleic anhydride.

20 41. The method of claim 40 wherein the average roughness of the inner surface is about 0.5 μm to about 0.8 μm and the concentration of PVP/maleic anhydride is about 1%.

25 42. The method of claim 40 wherein the inner surface has an average roughness of about 1.9 μm to about 2.1 μm and the concentration of PVP/maleic anhydride is about 1%.

43. The method of claim 40 wherein the average roughness of the inner surface is about 0.5 μm to about 0.8 μm and the concentration of maleic anhydride is about 1%.

30

VTN 632 USNP

44. The method of claim 40 wherein the inner surface has an average roughness of about 1.9 μm to about 2.1 μm and the concentration of maleic anhydride is about 1%.
- 5 45. A method of hydrating a contact lens comprising, consisting essentially of, or consisting of hydrating said lens in a molded base wherein said molded base comprises an additive.
- 10 46. The method of claim 45 wherein the additive is selected from the group consisting of succinic acid, glycerol monostearate, PVP, and PVP/maleic anhydride.
- 15 47. The method of claim 46 wherein the additives are present at a concentration of greater than about 0.25 weight percent to about 5 weight percent.
- 20 48. The method of claim 45 wherein the molded base further comprises a cavity formed in said molded base wherein said cavity comprises an inner surface, wherein said inner surface has an average roughness of about 0.5 μm to about 20 μm and the additive is maleic anhydride or PVP/maleic anhydride.